Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker SLDB
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | RA Capital Healthcare Fund, L.P. | 11.90M | 10.7% | SCHEDULE 13D/A ↗ |
| Nov 6, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Rajeev Shah | 12.04M | 10.8% | SCHEDULE 13D/A ↗ |
| Nov 6, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Peter Kolchinsky | 12.04M | 10.8% | SCHEDULE 13D/A ↗ |
| Nov 6, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | RA Capital Management, L.P. | 12.04M | 10.8% | SCHEDULE 13D/A ↗ |
| Aug 14, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Perceptive Xontogeny Venture Fund, LP | 73,107 | 0.1% | SCHEDULE 13D/A ↗ |
| Aug 14, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Perceptive Life Sciences Master Fund, Ltd. | 11.97M | 11.2% | SCHEDULE 13D/A ↗ |
| Aug 14, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Joseph Edelman | 12.05M | 11.2% | SCHEDULE 13D/A ↗ |
| Aug 14, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Perceptive Advisors LLC | 12.05M | 11.2% | SCHEDULE 13D/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Ryan Wilder | 4.83M | 4.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Vestal Point Capital, LP | 4.83M | 4.8% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G | SLDB Solid Biosciences Inc. | Abigail P. Johnson | 6.88M | 7.0% | SCHEDULE 13G ↗ |
| Aug 6, 2026 | SCHEDULE 13G | SLDB Solid Biosciences Inc. | FMR LLC | 6.88M | 7.0% | SCHEDULE 13G ↗ |
| Jul 30, 2026 | SCHEDULE 13G | SLDB Solid Biosciences Inc. | BlackRock, Inc. | 6.42M | 6.5% | SCHEDULE 13G ↗ |
| Jun 24, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | RA Capital Healthcare Fund, L.P. | 11.90M | 11.8% | SCHEDULE 13D/A ↗ |
| Jun 24, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Rajeev Shah | 12.04M | 11.9% | SCHEDULE 13D/A ↗ |
| Jun 24, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Peter Kolchinsky | 12.04M | 11.9% | SCHEDULE 13D/A ↗ |
| Jun 24, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | RA Capital Management, L.P. | 12.04M | 11.9% | SCHEDULE 13D/A ↗ |
| May 5, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Raymond Debbane | 10.07M | 10.0% | SCHEDULE 13G/A ↗ |
| May 5, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Ulys, L.L.C. | 1.37M | 1.4% | SCHEDULE 13G/A ↗ |
| May 5, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Avicenna Life Sci Master GP LLC | 1.37M | 1.4% | SCHEDULE 13G/A ↗ |
| May 5, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Avicenna Life Sci Master Fund LP | 1.37M | 1.4% | SCHEDULE 13G/A ↗ |
| May 5, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Siren, L.L.C. | 8.70M | 8.7% | SCHEDULE 13G/A ↗ |
| May 5, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Invus Global Management, LLC | 8.70M | 8.7% | SCHEDULE 13G/A ↗ |
| May 5, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Invus Public Equities Advisors, LLC | 8.70M | 8.7% | SCHEDULE 13G/A ↗ |
| May 5, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Invus Public Equities, L.P. | 8.70M | 8.7% | SCHEDULE 13G/A ↗ |
| Apr 27, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | BlackRock, Inc. | 4.58M | 4.7% | SCHEDULE 13G/A ↗ |
| Mar 17, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | RA Capital Healthcare Fund, L.P. | 9.18M | 9.8% | SCHEDULE 13D/A ↗ |
| Mar 17, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Rajeev Shah | 9.31M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 17, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Peter Kolchinsky | 9.31M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 17, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | RA Capital Management, L.P. | 9.31M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Perceptive Xontogeny Venture Fund, LP | 73,107 | 0.1% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Perceptive Life Sciences Master Fund, Ltd. | 11.90M | 12.8% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Joseph Edelman | 11.97M | 12.9% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Perceptive Advisors LLC | 11.97M | 12.9% | SCHEDULE 13D/A ↗ |
| Mar 10, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | RA Capital Healthcare Fund, L.P. | 9.53M | 9.8% | SCHEDULE 13D/A ↗ |
| Mar 10, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Rajeev Shah | 9.66M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 10, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Peter Kolchinsky | 9.66M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 10, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | RA Capital Management, L.P. | 9.66M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 10, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Bain Capital Life Sciences Opportunities IV, L.P. | 5.30M | 5.4% | SCHEDULE 13D/A ↗ |
| Mar 10, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | BCLS II Equity Opportunities, LP | 904,160 | 1.0% | SCHEDULE 13D/A ↗ |
| Mar 10, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | BCIP Life Sciences Associates, LP | 32,550 | 0.1% | SCHEDULE 13D/A ↗ |
| Mar 10, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | BCLS II Investco, LP | 8.60M | 8.8% | SCHEDULE 13D/A ↗ |
| Mar 10, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | Bain Capital Life Sciences Fund II, L.P. | 267,257 | 0.3% | SCHEDULE 13D/A ↗ |
| Mar 10, 2026 | SCHEDULE 13D/A (amended) | SLDB Solid Biosciences Inc. | BCLS SB Investco, LP | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | SLDB Solid Biosciences Inc. | Ryan Wilder | 5.82M | 7.5% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | SLDB Solid Biosciences Inc. | Vestal Point Capital, LP | 5.82M | 7.5% | SCHEDULE 13G ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Phillip Gross | 1.40M | 1.8% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Robert Atchinson | 1.40M | 1.8% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Adage Capital Management, L.P. | 1.40M | 1.8% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | SLDB Solid Biosciences Inc. | Phillip Gross | 4.00M | 5.1% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:55 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances